Watch our video-streamed launch show event and receive insights into our revolutionary new products: ambr® 250 ht perfusion and ambr® crossflow
You are guided through the show and being introduced to the highlights of our innovative solutions. Furthermore, two development partners are sharing their experience during the development process of the systems.
The revolution starts now.
Senior Vice President Marketing & Product Management,
Bioprocess Solutions at Sartorius Stedim Biotech is the host of our show and provides an overview of existing technologies, current innovations and an outlook for the bioprocess industry.
Product Manager at Sartorius Stedim Biotech will present the highlights of the ambr® 250 ht perfusion system.
Process Development Scientist, Pivotal Drug Substance Technologies at Amgen will describe the partnership that helped guide the development of the ambr® 250 ht perfusion.
John Betts, Product Development Scientist at Sartorius Stedim Biotech will present the highlights of the ambr® crossflow system.
Senior Principle Scientist at MSD will explain the partnership between MSD and Sartorius and how it lead to the development of the ambr® crossflow.
The High Throughput Solution For Parallel Screening
ambr® crossflow is a benchtop crossflow system for confirming the downstream manufacturability of biopharmaceuticals. It is a small-scale screening system with a minimum volume of 5 mL and a new range of ambr® CF filter cassettes with 10 cm² membrane area.
The Fast Track to Intensified Cell Culture Processes
ambr® 250 high throughput perfusion is a parallel bioreactor system for rapid development of scalable perfusion processes using 100 – 250 mL single-use bioreactors and a fully automated liquid handling platform.